Market Intelligence, Clinical Progress, and High-Purity Reagents for Next-Generation CFTR Corrector & Potentiator Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CFTR del F508 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (NBD1 Mutant) | CFTR del F508 NBD1 Mutant Recombinant Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. |
View CFTR del F508 Products |
| Gene Delivery | CFTR del F508 Lentivirus Premade Particles Full-length mutant ORF for stable cell lines. HEK293T packaged. Sequence Verified. Endotoxin <1EU/ug. |
View CFTR del F508 Products |
| Benchmark Ab | Anti-CFTR Recombinant Antibody (Sequence Verified) For surface trafficking detection by flow cytometry and Western blot. |
View CFTR del F508 Products |
| Validator | CFTR del F508 siRNA Set For specific knockdown and assay validation. Sequence Verified. |
View CFTR del F508 Products |
| Related Target A: WT CFTR | Wild-type CFTR ORF clones and lentivirus Reference control for functional recovery benchmarking. |
View CFTR Products |
| Related Target B: ENaC | SCNN1A (α-ENaC) Synergistic ion channel; hyperactivated in CF airway pathophysiology. |
View SCNN1A Products |
| Related Target C: Chaperone | HSP90AA1 ER quality control machinery; critical for corrector mechanism and folding studies. |
View HSP90AA1 Products |
| Related Target D: TMEM16A | TMEM16A (ANO1) Alternative calcium-activated chloride channel; bypass mechanism in cystic fibrosis. |
View TMEM16A Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ER Retention & Trafficking Defect | Stable lentivirus cell lines expressing del F508 mutant with documented ER retention phenotype; validated for brefeldin A washout trafficking assays. |
| Thermal Instability & Misfolding | Cell lysates from lentivirus-expressing cells; Sequence Verified mutant protein suitable for CETSA and thermal shift assays. |
| Channel Function Restoration | Cell pools with endogenous-like expression levels; Endotoxin controlled (<1EU/ug) for long-duration electrophysiology (Ussing chamber/patch clamp) compatibility. |
| Cross-species/Selectivity Liability | Human / Mouse / Cyno CFTR ortholog ORF clones available; high-purity recombinant NBD1 domains for SPR/DSF selectivity screening against other ABC transporters. |
| Assay Specificity Control | Sequence-verified CFTR siRNA included for knockdown confirmation and false-positive suppression. |
Live CFTR del F508 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for CFTR del F508 has been transformed by triple-combination modulators (e.g., elexacaftor/tezacaftor/ivacaftor), yet significant unmet need persists for patients with minimal function mutations and those requiring improved pulmonary function restoration. The race is intensifying toward next-generation correctors with superior ER-folding rescue efficiency and novel mechanisms targeting protein degradation pathways (e.g., premature termination codon readthrough, chaperone modulation). As first-generation therapies mature, the next wave of R&D is targeting genetic therapies (mRNA delivery, gene editing) and personalized corrector cocktails requiring precise mutant-specific assays. Emerging modalities like CRISPR-based gene editing and mRNA delivery aim to address underlying protein misfolding more permanently, while combination therapies with ENaC inhibitors and TMEM16A activators are gaining traction.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Corrector | Vertex, Flatley Discovery, Proteostasis (acquired) | Cystic Fibrosis (del F508 homozygous) | Trafficking Assay (Need stable del F508 lentivirus cell lines with high ER retention) |
| Small Molecule Potentiator | Vertex, Galapagos | Cystic Fibrosis (residual function) | Electrophysiology Cell Lines (Sequence Verified mutant expression) |
| Gene Therapy (AAV/mRNA) | 4D Molecular Therapeutics, Translate Bio (Sanofi), Arcturus | Cystic Fibrosis (all genotypes) | Transduction efficiency & expression validation (Need lentivirus benchmark, benchmark antibodies) |
| Degrader / PROTAC | AbbVie (discontinued), Emerging Biotechs, Academic consortia | Refractory CF | Selectivity Assay (Need precisely validated mutant vs WT protein for off-target screening) |